IL1B and COVID-19: In any case, treatment of COVID-19 patients with respiratory insufficiency and hyper inflammation with IL-1 inhibitors was associated with a significant reduction of mortality [83], indicating that at least during severe COVID-19 the overall effect of IL-1β is detrimental.